These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 12679437)

  • 1. Leptin and body fat in type 2 diabetes and monodrug therapy.
    Sivitz WI; Wayson SM; Bayless ML; Larson LF; Sinkey C; Bar RS; Haynes WG
    J Clin Endocrinol Metab; 2003 Apr; 88(4):1543-53. PubMed ID: 12679437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adiponectin and C-reactive protein in obesity, type 2 diabetes, and monodrug therapy.
    Putz DM; Goldner WS; Bar RS; Haynes WG; Sivitz WI
    Metabolism; 2004 Nov; 53(11):1454-61. PubMed ID: 15536601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass.
    Fischer S; Hanefeld M; Haffner SM; Fusch C; Schwanebeck U; Köhler C; Fücker K; Julius U
    Acta Diabetol; 2002 Sep; 39(3):105-10. PubMed ID: 12357293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of preconstituted, fixed combinations of low-dose glyburide plus metformin versus high-dose glyburide alone in the treatment of type 2 diabetic patients.
    Erle G; Lovise S; Stocchiero C; Lora L; Coppini A; Marchetti P; Merante D
    Acta Diabetol; 1999 Jun; 36(1-2):61-5. PubMed ID: 10436254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved glycemic control increases fasting plasma acylation-stimulating protein and decreases leptin concentrations in type II diabetic subjects.
    Ozata M; Gungor D; Turan M; Ozisik G; Bingol N; Ozgurtas T; Ozdemir IC
    J Clin Endocrinol Metab; 2001 Aug; 86(8):3659-64. PubMed ID: 11502793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.
    Freemark M; Bursey D
    Pediatrics; 2001 Apr; 107(4):E55. PubMed ID: 11335776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meformin, plasma glucose and free fatty acids in type II diabetic out-patients: results of a clinical study.
    Gregorio F; Ambrosi F; Manfrini S; Santucci A; Filipponi P
    Diabetes Res Clin Pract; 1997 Jul; 37(1):21-33. PubMed ID: 9279474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dietary treatment alone or diet with voglibose or glyburide on abdominal adipose tissue and metabolic abnormalities in patients with newly diagnosed type 2 diabetes.
    Takami K; Takeda N; Nakashima K; Takami R; Hayashi M; Ozeki S; Yamada A; Kokubo Y; Sato M; Kawachi S; Sasaki A; Yasuda K
    Diabetes Care; 2002 Apr; 25(4):658-62. PubMed ID: 11919121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship of regional adiposity to serum leptin level in nonobese Japanese type 2 diabetic male patients.
    Okumura T; Taniguchi A; Nagasaka S; Sakai M; Fukushima M; Kuroe A; Yoshii S; Nakamura T; Ogura M; Atarashi T; Nishida S; Nakai Y
    Diabetes Metab; 2003 Feb; 29(1):15-8. PubMed ID: 12629443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients.
    Miyazaki Y; Mahankali A; Wajcberg E; Bajaj M; Mandarino LJ; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4312-9. PubMed ID: 15356026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
    Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
    J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
    DeFronzo RA; Goodman AM
    N Engl J Med; 1995 Aug; 333(9):541-9. PubMed ID: 7623902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
    Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
    Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study.
    Gulias-Herrero A; Aguilar-Salinas CA; Gómez-Pérez FJ; Rull JA
    Diabetes Nutr Metab; 2003; 16(5-6):268-76. PubMed ID: 15000437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of long-term different diabetic therapies on plasma leptin in type 2 diabetic subjects.
    Huang CC; Lin JD; Chang HY
    Endocr J; 2001 Jun; 48(3):377-83. PubMed ID: 11523910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of regional adiposity to insulin resistance and serum triglyceride levels in nonobese Japanese type 2 diabetic patients.
    Taniguchi A; Nakai Y; Sakai M; Yoshii S; Hamanaka D; Hatae Y; Kawata M; Yamanouchi K; Okumura T; Doi K; Tokuyama K; Nagasaka S; Fukushima M
    Metabolism; 2002 May; 51(5):544-8. PubMed ID: 11979383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease.
    Nar A; Gedik O
    Acta Diabetol; 2009 Jun; 46(2):113-8. PubMed ID: 18839053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin ameliorates treatment of obese type 2 diabetic patients with mental retardation; its effects on eating behavior and serum leptin levels.
    Komori T; Yoshida F; Nakamura J; Miyazaki S; Miura H; Iguchi A
    Exp Clin Endocrinol Diabetes; 2004 Sep; 112(8):422-8. PubMed ID: 15372361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of insulin with or without continuation of oral hypoglycemic agents in the treatment of secondary failure in NIDDM patients.
    Chow CC; Tsang LW; Sorensen JP; Cockram CS
    Diabetes Care; 1995 Mar; 18(3):307-14. PubMed ID: 7555472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.